Literature DB >> 12716239

Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice.

Brian J Cuffel1, Francisca Azocar, Molly Tomlin, Shelly F Greenfield, Alisa B Busch, Thomas W Croghan.   

Abstract

BACKGROUND: Although published guidelines recommend the continuation of treatment for depression until full remission of symptoms and restoration of functioning, little is known about how often remission is achieved in usual practice and the precipitants of treatment termination when treatment outcome has not been optimal.
METHOD: A naturalistic study design examined 1859 patients receiving treatment for DSM-III-R major depression between 1995 and 1997 in the national provider network of a managed behavioral health organization (MBHO). Symptom and impairment ratings by clinicians were used to group patients into full remission, partial remission, and no response. Claims data were used to characterize treatment and identify comorbid medical conditions.
RESULTS: According to clinician ratings, approximately 27% to 39% of patients achieved full remission. Medical and substance use comorbidity and hospital admission were more common in those with a partial response to treatment. Only half of patients without a treatment response received a trial of medication during their treatment. Patient choice was the most common reason for termination of treatment, although nearly 40% of clinicians concurred with patients' decisions even when symptoms had not improved.
CONCLUSION: Although rates of full remission were comparable to those in clinical trials of antidepressants, results suggest that clinicians may fail to recommend continuation and maintenance treatment consistent with best practice guidelines and that unsuccessful treatment often does not include antidepressant medication.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12716239     DOI: 10.4088/jcp.v64n0406

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  7 in total

1.  Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder.

Authors:  Ramin Saghafi; Charlotte Brown; Meryl A Butters; Jill Cyranowski; Mary Amanda Dew; Ellen Frank; Ariel Gildengers; Jordan F Karp; Eric J Lenze; Francis Lotrich; Lynn Martire; Sati Mazumdar; Mark D Miller; Benoit H Mulsant; Elizabeth Weber; Ellen Whyte; Jennifer Morse; Jacqueline Stack; Patricia R Houck; Salem Bensasi; Charles F Reynolds
Journal:  Int J Geriatr Psychiatry       Date:  2007-11       Impact factor: 3.485

2.  Duloxetine in practice-based clinical settings: assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study.

Authors:  Madelaine M Wohlreich; Curtis G Wiltse; Durisala Desaiah; Wenyu Ye; Rebecca L Robinson; Kurt Kroenke; Susan G Kornstein; John H Greist
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

3.  Poor response to treatment: beyond medication.

Authors:  César Carvajal
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

4.  Do general practitioners and psychiatrists agree about defining cure from depression? The DEsCRIBE™ survey.

Authors:  Koen Demyttenaere; Marc Ansseau; Eric Constant; Adelin Albert; Geert Van Gassen; Kees van Heeringen
Journal:  BMC Psychiatry       Date:  2011-10-14       Impact factor: 3.630

5.  Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis.

Authors:  Marliese Y Dawson; Erin E Michalak; Paul Waraich; J Ellen Anderson; Raymond W Lam
Journal:  BMC Fam Pract       Date:  2004-09-07       Impact factor: 2.497

Review 6.  The Impact of Residual Symptoms in Major Depression.

Authors:  Joshua A Israel
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-03

Review 7.  Animal models of major depression: drawbacks and challenges.

Authors:  Barbara Planchez; Alexandre Surget; Catherine Belzung
Journal:  J Neural Transm (Vienna)       Date:  2019-10-04       Impact factor: 3.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.